| Literature DB >> 25712365 |
Pharath Lim1, Dalin Dek2, Vorleak Try2, Sokunthea Sreng2, Seila Suon2, Rick M Fairhurst3.
Abstract
Dihydroartemisinin-piperaquine is the current frontline artemisinin combination therapy (ACT) for Plasmodium falciparum malaria in Cambodia but is now failing in several western provinces. To investigate artesunate plus mefloquine (AS+MQ) as a replacement ACT, we measured the prevalence of multiple pfmdr1 copies--a molecular marker for MQ resistance--in 844 P. falciparum clinical isolates collected in 2008 to 2013. The pfmdr1 copy number is decreasing in Western Cambodia, suggesting that P. falciparum is regaining in vitro susceptibility to MQ.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25712365 PMCID: PMC4394809 DOI: 10.1128/AAC.05163-14
Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN: 0066-4804 Impact factor: 5.191